25+ ME/CFS Phenotyping List
- Aug 26, 2025
- 8 min read
Clinical and Social Terrain Subtypes in ME/CFS
By Cynthia Adinig
Executive Summary
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has historically been treated in research and clinical care as though it were a single uniform disease entity. Increasing evidence suggests this assumption is biologically inaccurate and has contributed substantially to failed clinical trials, inconsistent therapeutic outcomes, diagnostic confusion, poor reproducibility, and widespread patient harm (Institute of Medicine, 2015; Komaroff and Lipkin, 2021; Wirth and Scheibenbogen, 2021). ME/CFS is increasingly recognized as a heterogeneous neuroimmune condition involving overlapping but distinct patterns of post-exertional symptom exacerbation (PEM), autonomic dysfunction, immune dysregulation, neuroinflammation, mitochondrial instability, mast-cell activation, endocrine fluctuation, cognitive impairment, environmental sensitivity, and relapse-sensitive disease behavior.
Failure to stratify these patterns has produced major downstream consequences. Clinical trials frequently combine biologically incompatible patient populations into generalized cohorts, diluting therapeutic signal and obscuring subgroup-specific response patterns. Patients with severe PEM may be grouped alongside milder autonomic-dominant populations. Mast-cell-sensitive patients may be interpreted as medication intolerant rather than physiologically reactive. Viral-onset and trauma-associated cohorts may be analyzed together despite potentially different inflammatory pathways, resilience profiles, and therapeutic needs. The result has been a research environment that often mistakes heterogeneity for inconsistency rather than recognizing it as a defining feature of the disease itself (Hornig et al., 2015; Bateman et al., 2021; Raj et al., 2020).
The CYNAERA 25 Core ME/CFS Phenotyping List was developed to address this structural gap through a terrain-aware classification framework integrating biologic, environmental, autonomic, endocrine, functional, and social determinants of disease behavior. Rather than assuming ME/CFS presents identically across patients, the framework recognizes that symptom expression, relapse dynamics, treatment tolerability, and functional limitation are shaped by interacting physiologic systems and environmental pressures across time.
This phenotyping system is intended to serve as:
a foundation for adaptive and phenotype-aware clinical trial design
a roadmap for individualized and longitudinal patient care
a framework for more biologically coherent subgroup analysis
a tool for access-aware and equity-aware research that includes vulnerable, severe, underdiagnosed, and structurally overlooked populations
a systems-level infrastructure for integrating digital biomarkers, environmental overlays, flare modeling, and longitudinal resilience tracking into future neuroimmune research
The framework also reflects growing recognition that ME/CFS exists within a broader landscape of infection-associated chronic conditions (IACCs) that includes Long COVID, dysautonomia, MCAS, connective tissue disorders, and related post-viral neuroimmune illnesses. These conditions frequently overlap biologically and clinically, suggesting that future therapeutic development may require dynamic, state-dependent trial architecture rather than rigid diagnosis-based models alone (Proal and VanElzakker, 2021; Yong, 2021).
Importantly, the CYNAERA approach treats heterogeneity not as statistical noise to be minimized, but as biologically meaningful signal capable of improving therapeutic interpretation when properly structured. By organizing patients according to dominant instability patterns, relapse behavior, autonomic function, inflammatory activity, environmental sensitivity, and exertional response, future research systems may become substantially more capable of identifying meaningful treatment response while reducing false negatives and subgroup dilution.
The broader implication is clear: ME/CFS research will likely continue to struggle until trial systems, diagnostic frameworks, and therapeutic models reflect the dynamic and heterogeneous reality of the disease itself.
Core Domains of Phenotyping
Formula: Phenotype = Core Axis × Trigger/Modulator + Functional Signature
1. Energy Dysregulation Axis
PEM-Dominant Classic – exertion → multi-day crash.
Cognitive PEM – mental effort triggers relapse.
Delayed-Onset PEM – crash 24–72h after trigger.
Remission-Relapse Oscillator – alternating stable & crash states.
Adrenergic Reserve – compensates via stress hormones, then collapse.
2. Autonomic & Circulatory Axis
POTS-Dominant – tachycardia, orthostatic intolerance.
Orthostatic Intolerance (Non-Tachycardic) – dizziness/fatigue without HR spike.
Blood Volume/Perfusion Variant – low plasma volume, poor circulation.
Baroreflex Dysregulation – unstable BP with gravity stressors.
3. Neuro-Immune & Sensory Axis
Neuroinflammatory Brain Fog – cognitive slowing, cytokine-driven.
Sensory Overload Dominant – light, sound, smell hypersensitivity.
Cognitive-Motor Coordination Decline – motor planning + thinking impaired.
Visual-Spatial Lag – delayed motion/space processing.
4. Hormonal & Endocrine Axis
Cycle-Triggered PEM – symptom worsening with menstruation.
Estrogen Withdrawal Subtype – crashes during peri-/post-menopause.
HPA Axis Dysfunction – adrenal/hypothalamic imbalance.
Postpartum Collapse – immune-hormonal breakdown post-birth.
5. Immune, Infection & Reactivation Axis
EBV/HHV-6 Reactivation Subtype – episodic flares.
Low NK Cell Immunodeficiency – recurrent infections, poor clearance.
Post-Viral Chronic Onset – mono/flu/COVID as initiating trigger.
Steroid-Triggered Relapser – immune suppression → viral rebound.
6. Sleep & Pain Axis
Non-Restorative Sleep Core – poor restorative function despite hours slept.
Sleep-Wake Reversal – flipped circadian cycles.
Migraine/Pain-Dominant – headaches, muscle spasm, neuropathic pain.
Neuro-Excitability Subtype – EEG abnormalities, seizure-like flares.
7. Social, Demographic & Access Constrained
These don’t define phenotypes alone but modify severity, access, and progression:
BIPOC Misdiagnosed Variant – dismissed as depression/anxiety.
Low-Income/Access Barrier – worsened by untreated flares, poor care.
Pediatric Misattribution – mislabeled as anxiety/behavioral.
Men Misdiagnosed as Burnout – gendered undercounting.
Mold/Housing Overlay – environmental driver of relapse.
Food Insecurity Overlay – malnutrition worsening PEM.
Why This Matters
Clinical Trials: Stratification into these phenotypes prevents dilution of signals, reduces dropouts, and enables biomarker-linked subgrouping (Fluge & Mella, 2019; Bateman et al., 2021).
Clinical Care: Recognizes terrain-specific vulnerabilities such as hormonal modulation, reactivation triggers, or environmental stressors (Hornig et al., 2015).
Accuracy: Includes structural and social barriers (late diagnosis, BIPOC misclassification, food insecurity), which are routinely excluded from research yet shape disease trajectory (Wong et al., 2023).
Conclusion
ME/CFS is not a static or uniform illness, and future research systems cannot continue operating as though it is. The repeated failure of conventional clinical trial architecture to generate reproducible therapeutic breakthroughs reflects not only the complexity of the disease, but the inadequacy of systems designed for far more stable conditions. Patients with fundamentally different autonomic profiles, inflammatory behavior, environmental sensitivity, PEM severity, endocrine instability, and resilience capacity have historically been grouped together under overly broad frameworks that obscure meaningful biologic patterns.
The CYNAERA 25 Core ME/CFS Phenotyping List proposes a different direction. By integrating biologic, environmental, autonomic, endocrine, functional, and structural variables into a terrain-aware classification framework, the system shifts ME/CFS interpretation away from rigid one-size-fits-all models toward dynamic phenotype-based analysis. This approach may improve clinical trial design, therapeutic targeting, endpoint interpretation, relapse prediction, and longitudinal patient care while reducing subgroup dilution and false-negative outcomes.
Importantly, this framework is not intended to fragment the ME/CFS community into isolated categories. Its purpose is the opposite: to create more biologically coherent systems capable of explaining why patients with the same diagnosis may experience profoundly different symptom patterns, treatment tolerability, progression trajectories, and recovery behavior. Recognizing heterogeneity does not weaken the legitimacy of ME/CFS. It strengthens the ability to study and treat it accurately.
This systems-level approach also has implications extending beyond ME/CFS alone. Long COVID, dysautonomia, MCAS, connective tissue disorders, autoimmune disease, and broader post-infectious neuroimmune illnesses increasingly demonstrate overlapping biologic and functional patterns that challenge traditional disease silos. Future therapeutic infrastructure will likely depend on adaptive, phenotype-aware, and longitudinal frameworks capable of interpreting dynamic neuroimmune terrain across conditions rather than relying exclusively on static diagnosis categories. The central message of this paper is straightforward: heterogeneity is not the failure of ME/CFS research. Failure to account for heterogeneity is.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration. For media, podcast, research, or licensing inquiries related to the Mankeeping Index™, contact CYNAERA.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Bateman, L., Rowe, P. C., & Montoya, J. G. (2021). Post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Pediatrics, 9, 707819.
Fluge, Ø., & Mella, O. (2019). Clinical trials of B-cell depletion therapy for myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Immunology, 10, 1225.
Hornig, M., Montoya, J. G., Klimas, N., Levine, S., Felsenstein, D., Bateman, L., ... & Lipkin, W. I. (2015). Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Science Advances, 1(1), e1400121.
Institute of Medicine (IOM). (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press.
Komaroff, A. L. (2021). Advances in understanding the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome. Nature Reviews Disease Primers, 7, 68.
Wong, T. L., Weitz, J. S., Adinig, C., et al. (2023). Findings from an online survey of people with long COVID: Characterization and impact. medRxiv.
Comments